Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis

Molecular Pharmacology

Volumn 62, Issue 3, 2002, Pages 514-520

  Zhang, W ^a   Ke, H ^b   Colman, R W ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; BENZAMIDINE; CILOSTAZOL; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; LEUPEPTIN; MILRINONE; PEPSTATIN; PHOSPHODIESTERASE INHIBITOR; SOYBEAN TRYPSIN INHIBITOR; TOSYLPHENYLALANYL CHLOROMETHYL KETONE;

ARTICLE; BACULOVIRUS; DRUG BINDING; DRUG POTENCY; DRUG SENSITIVITY; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; BINDING SITES; HUMANS; MILRINONE; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PHOSPHODIESTERASE INHIBITORS; TETRAZOLES;

EID: 0036765991     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.3.514     Document Type: Article

References (22)

1. Atienza JM, Susanto D, Huang C, McCarty AS, and Colicelli J (1999) Identification of inhibitor specificity determinants in a mammalian phosphodiesterase. J Biol Chem 274:4839-4847.
2. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, et al. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D54:905-921.
3. Beebe HHG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, and Forbes WP (1999) A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 27;159:2041-2050.
4. Cheung PP, Xu H, McLaughlin MM, Ghazaleh FA, Livi GP, and Colman RW (1996) Human platelet cGI-PDE: expression in yeast and localization of the catalytic domain by deletion mutagenesis. Blood 88:1321-1329.
5. Dawson DL (2001) Comparative effects of cilostazol and other therapies for intermittent claudication. Am J Cardiol 87:19D-27D.
6. El-Beyrouty C and Spinler SA (2001) Cilostazol for prevention of thrombosis and restenosis after intracoronary stetting. Ann Pharmacother 35:1108-1113.
7. Hidaka H and Asano T (1976) Platelet cyclic 3′:5′-nucleotide phosphodiesterase released by thrombin and calcium ionophore. J Biol Chem 251:7508-7516.
8. Hidaka H and Endo T (1984) Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase - basic and potential clinical applications. Adv Cyclic Nucleotide Protein Phosphorylation Res 16:245-259.
9. Jacobitz S, McLaughlin MM, Livi GP, Burman M, and Torphy TJ (1996) Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding (1996) Mol Pharmacol 50:891-899.
10. Jones T. A., Zou, J-Y., Cowan S. W. & Kjeldgaard M (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A47:110-119.
11. Kikura M and Levy JH (1995) New cardiac drugs. Int Anesthesiol Clin 33:21-37.
12. Kishi T, Nakahashi K, Ito H, Taniguchi S, and Takaki M (2001) Effects of milrinone on left ventricular end-systolic pressure-volume relationship of rat hearts in situ. Clin Exp Pharmacol Physiol 28:737-742.
13. Mills DC, Puri R, Hu CJ, Minniti C, Grana G, Freedmm MD, Colman RF, and Colman RW (1992) Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 12:430-436.
14. Polymeropoulos EE and Hofgen N (1999) Quant Struct-Act Rlat 18:543.
15. Robertson DW, Jones ND, Krushinski JH, Pollock GD, Swarzendruber JK, Hayes JS (1987) Molecular structure of the dihydropyridazinone cardiotonic 1,3-dihydro3,3-dimethyl-5-(1,4,g,6-tetrahydro-6-oxo-pyridazinyl)- 2H-inol-2-one, a potent inhibitor of cyclic AMP phosphodiesterase. J Med Chem 30:63-627.
16. Richter W, Unciuleac L, Hermsdorf T, Kronbach T, and Detter D (2001) Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4. Cell Signal 13:287-297.
17. Tanabe Y, Ito E, Nakagawa I, and Suzuki K (2001) Effect of ciostazol on restenosis after coronary angioplasty md stenting in comparison to conventional coronary artery stenting with ticlopidine. Int J Cardiol 78:285-291.
18. Turko IV, Francis SH, and Corbin JD (1998) Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase. J Biol Chem 273, 6460-6466.
19. Turko IV, Ballard SA, Francis SH, and Corbin JD (1999) Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by ildenafil and related compounds. Mol Pharmacol 56:124-130.
20. Xu RX, Hassell AM, Vanderwall D, Lambert MH, Holmes WD, Luther MA, Rocque WJ, Milburn MV, Zhao Y, Ke H, et al. (2000) Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science (Wash DC) 288:1822-1825.
21. Zhang W and Colman RW (2000) Conserved amino acids in metal-binding motifs of PDE3A are involved in substrate and inhibitor binding. Blood 95, 3380-3386.
22. Zhang W, Ke H, Tretiakova AP, Jameson B, and Colman RW (2001) Identification of overlapping but distinct cAMp md cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagunesis and molecular modeling based on crystaillne PDE4B. Protein Sci 10:1481-1489.